To The Moon

Very Quickly.

This is a continuation post from my previous. click here for the first, Repost to share ok. Tks!

As there are 7 penny stocks to cover, I shall jump straight into it.

#7. $Personalis(PSNL)$

• Nbr of Billionaire Holders: 5

• 1-Year Gain (as of 25 Apr 2025): +204.76%

• Share Price (as of 25 Apr 2025): $3.84

Facts & Figures.

• PSNL is a diagnostic & research company that develops markets and sells advanced cancer genomic tests and services.

• It offers NeXT Personal, a tumor-informed liquid biopsy test for the detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumour cancers.

• While the stock is up by +204.76% over the past year, Craig Hallum still initiated coverage of the stock with a “Buy” recommendation on 17 Mar 2025.

Growth & Partnership.

• 2024 saw PSNL presenting compelling clinical data at medical conferences, as it also drove testing growth by 52%.

• In addition, PSNL strengthened its long-term prospects with (a) a $50 million strategic investment from Merck and (b) inked a commercial collaboration with Moderna.

• The partnership with Moderna for V940/mRNA-4157 places PSNL, in a leading role in the advancement of personalized neoantigen therapy.

• The ongoing choice of their ImmunoID NeXT Platform highlights its technical excellence in tumor profiling and neoantigen discovery.

• The platform’s capability to facilitate the development of tailored cancer vaccines provides a significant competitive edge in the swiftly changing precision oncology arena.

#6. Butterfly Network, Inc. (NYSE:BFLY)

• Nbr of Billionaire Holders: 7

• 1-Year Gain (as of 25 Apr 2025): +212.82%

• Share Price (as of 25 Apr 2025): $2.44

Facts & Figures.

• BFLY is a healthcare company that develops & markets affordable, accessible medical imaging tools.

• Its core technology is the “Ultrasound-on-Chip™” that enables creation of a single-probe, whole-body ultrasound system, setting it apart in the healthcare technology sector.

• BFLY has rallied by +225% over the past 12 months amid growing expectations that robust revenue growth will propel it to profitability.

Analyst’s Rating.

• On 17 Mar 2025, William Blair initiated coverage of the stock with an “Outperform” recommendation. (see above)

Quarterly Earnings.

BFLY has handed in an excellent earnings report card for Q4 2024:

• Revenue: came in at $22.35 million, that was a +35.33% YoY gain.

• Loss per share (diluted): was a negligible -$0.08; that was a +61.9% YoY improvement.

• Net loss: was a -18.1 million, that was a +58.97% YoY improvement.

BFLY’s transition to the more profitable iQ3 device was the catalyst behind product revenue increasing +45% YoY, coupled with its successful reduced its net loss. (see above)

Butterfly Network has laid down strategic plans to meet long-term financial goals.

These include:

• Achieve a $500 million revenue goal in 5 years and cash flow breakeven by 2027.

• One of its strategic moves is to establish a new company, Octiv, to market ultrasound technology in new industries.

• With $92.8 million in cash, BFLY remains in a strong financial position to invest in key growth strategies.

#5. $Clover Health Corp(CLOV)$

• Nbr of Billionaire Holders: 7

• 1-Year Gain (as of 25 Apr 2025): +411.94%

• Share Price (as of 25 Apr 2025): $3.43

Facts & Figures.

• CLOV is a healthcare company that provides Medicare Advantage plans.

• Using a data-driven approach, it offers preferred provider organization and health maintenance organization plans to Medicare-eligible individuals.

• The stock has rallied by about +410% over the past 12 months as investors react to a significant growth in its Medicare Advantage membership.

Financial Status.

• CLOV’s flagship PPO plan has been upgraded to a 4-star rating by the Centers for Medicare and Medicaid Services.

• The robust membership growth surpassed the 100,000 level, was the catalyst behind CLOV’s deliverance of a +9% increase in insurance revenue to $1.3 billion.

• Leading to CLOV achieving profitability in FY 2024, with EBITDA rising by +$112 million to reach $70 million.

• For 2025, CLOV projects the underlying growth with a +30% YoY increase in Average Medicare Advantage membership.

• Guidance for 2025 insurance revenue is between $1.8 - $1.875 billion.

Analyst’s Rating.

On 08 Apr 2025, Canaccord Genuity reaffirmed (a) a “Buy” rating and (b) a price target of $4.50 for CLOV.

It cited strong growth prospects and sector sentiment improvement as the main factors.

CLOV’s robust performance, boosted by 4-Star rating reimbursements and revenue growth, positions it well for future expansion in 2026.

#4. Xeris Biopharma Holdings Inc. (NASDAQ:XERS)

• Nbr of Billionaire Holders: 7

• 1-Year Gain (as of 25 Apr 2025): +146.29%

• Share Price (as of 25 Apr 2025): $4.31

Facts & Figures.

• XERS is a biopharmaceutical company that develops and commercializes innovative therapies across endocrinology, neurology, and gastroenterology segments.

• XERS focuses on developing products using its proprietary XeriSol & XeriJect technology platforms.

• Stock has been up by +130.90% over the past 12 months, thanks to continued momentum in its commercial business.

Company’s Growth & Products.

In 2024, XERS’s total revenue reached a record $203 million. This was a +24% increase from FY 2023’s $163.9 million.

2024 strong revenue growth was mainly driven by 3 key products:

• Recorlev (for Cushing’s syndrome): Revenue jumped by 118%, reaching over $64 million, thanks to more new patient starts and referrals.

• Gvoke (for severe hypoglycemia): Revenue grew by 24%, totaling nearly $83 million, showing steady market demand.

• Keveyis (for primary periodic paralysis): Revenue was about $50 million, with a stable patient base, even though sales declined by -13% compared to previous year.

Combined performance of Recorlev, Gvoke, and Keveyis was the main reason for XERS’s record-breaking results in 2024.

Financial Standings.

• For FY 2024, XERS also trimmed its net loss to -$54.8 million from $62.3 million a year ago.

• For FY 2025, XERS projected continual growth of between $255 - $275 million, that would be over +30% higher at the midpoint compared to 2024, to be driven by the substantial upside potential of XP8121, a treatment for hypothyroidism.

#3. $fuboTV Inc.(FUBO)$.

• Nbr of Billionaire Holders: 8

• 1-Year Gain (as of 25 Apr 2025): +115.71%.

• Share Price (as of 25 Apr 2025): $3.02.

Facts & Figures.

• FUBO is a commercial services company providing live TV streaming services.

• It aggregates a wide range of premium sports, news, and entertainment content into a user-friendly app, aiming to revolutionize the current television model.

• It has exploded over the past year, rallying by +115.71% on striking a strategic partnership with theme park giant Disney.

Facts & Figures.

• The deal paves the way for the iconic media juggernaut to own at least a 70% stake in FUBO.

• It will add a layer of credibility, scalability, and liquidity, strengthening FUBO’s prospects in the live streaming business.

• Additionally, strengthen FUBO’s competitive edge as it seeks to target more than 20 million US homes that subscribe to live TV streaming.

Revenue Growth.

• Increased focus on innovation and subscriber monetization has also bolstered FUBO’s growth avenues.

• Its average revenue per user surged to a record high of $87.90 in North America in Q4 2024.

• FUBO achieved free cash flow for the first time, with improved operational efficiency.

It explained why it is one of the best multi-bagger penny stocks to buy, according to billionaires.

#2. $CommScope(COMM)$

• Nbr of Billionaire Holders: 8

• 1-Year Gain (as of 25 Apr 2025): +298.98%.

• Share Price (as of 25 Apr 2025): $3.91

Facts & Figures.

• COMM is a communication equipment company providing infrastructure solutions for communications, data centers, and entertainment networks worldwide.

• It offers (a) fiber optic & copper connectivity and (b) cable solutions for telecommunications. The stock has been on a roll, rallying +298.98% over the past 12 months.

Key Factors / Earnings.

• COMM’s impressive run comes from being the global leader in network connectivity solutions.

• As a result, it delivered a strong financial result that underscore underlying growth.

• In Q4 2024, Net sales were up +26.6% to $1.17 billion, with overall higher sales across all segments.

• Its operational loss also improved markedly from Q4 2023’s -$414 million to -$65.2 million, a year later.

• COMM generated operational cash flow of $273.1 million and with free cash flow (FCF) of $247.8 million.

Credit Rating’s Revisit.

• Moody’s upgraded COMM’s credit rating to Caa1 from Caa2.

• At the same time, it tagged a “B3” rating to its senior secured term loan.

These upgrade reflects COMM’s successful refinancing of debt due 2025 & 2026 through asset sales and new secured debt.

#1. $Lumen Technologies(LUMN)$.

• Nbr of Billionaire Holders: 9

• 1-Year Gain (as of 25 Apr 2025): +174.59%.

• Share Price (as of 25 Apr 2025): $3.35.

Facts & Figure.

• LUMN is a telecommunications company that offers communications, network services, security, cloud solutions, voice, and managed services through its fiber optic and copper networks.

• Up by +174.59% over the past 12 months, it is turning out to be one of the best multi-bagger penny stocks to buy, according to billionaires.

Strategic Partnerships.

• LUMN has benefitted from the artificial intelligence (AI) spectacle.

• It has initiated strategic partnerships with Microsoft, Meta Platforms, and other leading tech companies that require increased connectivity between their data centres.

• LUMN has also partnered with Google Cloud to provide advanced cloud & network solutions to meet growing needs for AI workloads.

Forward Guidance / Outlook.

• As more businesses adopt AI, the need for LUMN’s reliable & efficient networking solutions should soar.

• By teaming up with tech giants in the midst of AI push, LUMN has strengthened and diversified its revenue streams.

• Its partnerships should enhance its top line and competitive edge in the industry.

On 21 Feb 2025, Wells Fargo, Snr equity analyst, Erick Luebchow upgraded LUMN to “Equal weight” from “Underweight” and a price target of $5.

My viewpoints: (mine only)

I don’t know if you noticed, there seems to be quite a number of healthcare penny stocks that billionaires are vested in.

This is followed by Basic materials, Communication services and finally Technology.

Having had many run-ins with healthcare stocks that reverse-split until they became worthless, I will avoid them at all costs.

These stocks already have a fantastic run and posted huge gains. Might be prudent to wait for pullbacks before consider taking a stake.

That will be my strategy, what’s yours ?

Must Read: Click on below titles to access. Repost to share, Like as encouragement ok. Thanks.

• TMQ, CVRS, NGD : US stocks Billionaires Buy.

• Jobs & Earnings Rock US Market This Week ?

• ENB : Stable stock in a Volatile US market ?

• Do you think there is/are any penny stocks that catch your attention ?

• Do you think healthcare stocks are worthy or risky bets ?

If you find this post interesting, give it wings! ️ Repost and share the insights ?

Do consider “Follow me” and get firsthand read of my daily new post. Thank you.

@Daily_Discussion

@TigerPM

@TigerStars

@Tiger_SG

@TigerEvents